These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34784942)

  • 1. Italian national consensus statement on management and pharmacological treatment of phenylketonuria.
    Burlina A; Biasucci G; Carbone MT; Cazzorla C; Paci S; Pochiero F; Spada M; Tummolo A; Zuvadelli J; Leuzzi V
    Orphanet J Rare Dis; 2021 Nov; 16(1):476. PubMed ID: 34784942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations.
    Cunningham A; Rohr F; Splett P; Mofidi S; Bausell H; Stembridge A; Kenneson A; Singh RH
    Orphanet J Rare Dis; 2023 Jun; 18(1):155. PubMed ID: 37349772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
    Trefz FK; Belanger-Quintana A
    Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of phenylketonuria in adult patients in Italy: a survey of six specialist metabolic centers.
    Burlina A; Leuzzi V; Spada M; Carbone MT; Paci S; Tummolo A
    Curr Med Res Opin; 2021 Mar; 37(3):411-421. PubMed ID: 33222540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
    Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
    Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with phenylketonuria (PKU) under enzyme replacement therapy: An Italian model (expert opinion).
    Scala I; Brodosi L; Rovelli V; Noto D; Burlina A
    Mol Genet Metab Rep; 2024 Jun; 39():101065. PubMed ID: 38425869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria.
    Longo N; Dimmock D; Levy H; Viau K; Bausell H; Bilder DA; Burton B; Gross C; Northrup H; Rohr F; Sacharow S; Sanchez-Valle A; Stuy M; Thomas J; Vockley J; Zori R; Harding CO
    Genet Med; 2019 Aug; 21(8):1851-1867. PubMed ID: 30546086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
    Winn SR; Scherer T; Thöny B; Harding CO
    Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency.
    Blau N
    Expert Rev Endocrinol Metab; 2010 Jul; 5(4):483-494. PubMed ID: 30780801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.
    Utz JR; Lorentz CP; Markowitz D; Rudser KD; Diethelm-Okita B; Erickson D; Whitley CB
    Mol Genet Metab; 2012 Feb; 105(2):193-7. PubMed ID: 22112818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
    Burnett JR
    IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency.
    Cerone R; Andria G; Giovannini M; Leuzzi V; Riva E; Burlina A
    Adv Ther; 2013 Mar; 30(3):212-28. PubMed ID: 23436109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the use of sapropterin in phenylketonuria.
    Cunningham A; Bausell H; Brown M; Chapman M; DeFouw K; Ernst S; McClure J; McCune H; O'Steen D; Pender A; Skrabal J; Wessel A; Jurecki E; Shediac R; Prasad S; Gillis J; Cederbaum S
    Mol Genet Metab; 2012 Jul; 106(3):269-76. PubMed ID: 22575621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylketonuria Scientific Review Conference: state of the science and future research needs.
    Camp KM; Parisi MA; Acosta PB; Berry GT; Bilder DA; Blau N; Bodamer OA; Brosco JP; Brown CS; Burlina AB; Burton BK; Chang CS; Coates PM; Cunningham AC; Dobrowolski SF; Ferguson JH; Franklin TD; Frazier DM; Grange DK; Greene CL; Groft SC; Harding CO; Howell RR; Huntington KL; Hyatt-Knorr HD; Jevaji IP; Levy HL; Lichter-Konecki U; Lindegren ML; Lloyd-Puryear MA; Matalon K; MacDonald A; McPheeters ML; Mitchell JJ; Mofidi S; Moseley KD; Mueller CM; Mulberg AE; Nerurkar LS; Ogata BN; Pariser AR; Prasad S; Pridjian G; Rasmussen SA; Reddy UM; Rohr FJ; Singh RH; Sirrs SM; Stremer SE; Tagle DA; Thompson SM; Urv TK; Utz JR; van Spronsen F; Vockley J; Waisbren SE; Weglicki LS; White DA; Whitley CB; Wilfond BS; Yannicelli S; Young JM
    Mol Genet Metab; 2014 Jun; 112(2):87-122. PubMed ID: 24667081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally invasive (13)C-breath test to examine phenylalanine metabolism in children with phenylketonuria.
    Turki A; Murthy G; Ueda K; Cheng B; Giezen A; Stockler-Ipsiroglu S; Elango R
    Mol Genet Metab; 2015; 115(2-3):78-83. PubMed ID: 25943030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.